Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.

Eliasson J, Hvistendahl MK, Freund N, Bolognani F, Meyer C, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition7 Sept 2021Cited by 40 (Europe PMC)

PMID34287970PMCIDPMC9292678DOI10.1002/jpen.2223PepBankPUB-34287970

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, mild to moderate treatment-related polyuria occurred with apraglutide.
In plain wordsIn adults with SBS-IF, apraglutide treatment caused mild to moderate excessive urination.
Peptide
Apraglutide
Outcome
Not applicablePolyuria
Study
n = 8
Analysis
Primary
Outcome group
Adverse events · Kidney and urinary
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797001
02HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, decreased stoma output was a mild to moderate treatment-related event with apraglutide.
In plain wordsIn adults with SBS-IF, reduced stoma output was a mild to moderate event related to apraglutide treatment.
Peptide
Apraglutide
Outcome
Not applicableDecreased stoma output
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797002
03HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, mild to moderate treatment-related stoma complications occurred with apraglutide.
In plain wordsIn adults with SBS-IF, mild to moderate stoma complications occurred with apraglutide treatment.
Peptide
Apraglutide
Outcome
Not applicableStoma complications
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797003
04HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, decreased thirst was a mild to moderate treatment-related event with apraglutide.
In plain wordsIn adults with SBS-IF, reduced thirst was a mild to moderate event related to apraglutide treatment.
Peptide
Apraglutide
Outcome
Not applicableDecreased thirst
Study
n = 8
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797004
05HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, mild to moderate treatment-related edema occurred with apraglutide.
In plain wordsIn adults with SBS-IF, mild to moderate swelling occurred with apraglutide treatment.
Peptide
Apraglutide
Outcome
Not applicableEdema
Study
n = 8
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797005
06HumanRandomized controlled trialSafety outcome
In adults with SBS-IF, no serious adverse events were considered related to apraglutide.
In plain wordsIn adults with SBS-IF, no serious adverse events were considered related to apraglutide.
Peptide
Apraglutide
Outcome
Not applicableTreatment-related serious adverse events
Study
n = 8
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
No serious AEs were considered to be related to apraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797006
07HumanRandomized controlled trialEfficacy outcome
In adults with SBS-IF, apraglutide increased urine output by 714 ml/day versus placebo.
In plain wordsIn adults with SBS-IF, apraglutide increased urine output by 714 ml/day more than placebo.
Peptide
Apraglutide
Outcome
IncreaseUrine volume output
Study
n = 8
Comparator
placebo
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg once weekly · 4 weeksAs given in this study (human).
Measurements
Adjusted mean urine output increase
714 ml/day
5 mg
Source sentences
Summary
Treatment with once-weekly 5- and 10-mg apraglutide doses significantly increased urine volume output by an adjusted mean of 714 ml/day (95% CI, 490-939; P < .05) and 795 ml/day (95% CI, 195-1394; P < .05), respectively, compared with placebo, with no significant differences between doses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797008
08HumanNon-randomized trialSafety outcome
In adults with SBS-IF, apraglutide safety profiles were comparable between lower and higher doses.
In plain wordsIn adults with SBS-IF, lower and higher apraglutide doses had similar safety profiles.
Peptide
Apraglutide
Outcome
No significant changeSafety profile by dose
Study
n = 8
Comparator
lower versus higher apraglutide dose
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
The safety profile was comparable for the lower and higher doses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797007
09HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF, apraglutide increased urine output by 795 ml/day versus placebo.
In plain wordsIn adults with SBS-IF, apraglutide increased urine output by 795 ml/day more than placebo.
Peptide
Apraglutide
Outcome
IncreaseUrine volume output
Study
n = 8
Comparator
placebo
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 mg once weekly · 4 weeksAs given in this study (human).
Measurements
Adjusted mean urine output increase
795 ml/day
10 mg
Source sentences
Summary
Treatment with once-weekly 5- and 10-mg apraglutide doses significantly increased urine volume output by an adjusted mean of 714 ml/day (95% CI, 490-939; P < .05) and 795 ml/day (95% CI, 195-1394; P < .05), respectively, compared with placebo, with no significant differences between doses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797009
10HumanNon-randomized trialEfficacy outcome
In adults with SBS-IF, urine output did not differ significantly between apraglutide doses.
In plain wordsIn adults with SBS-IF, urine output did not differ significantly between apraglutide doses.
Peptide
Apraglutide
Outcome
No significant changeUrine output difference between doses
Study
n = 8
Comparator
5 mg versus 10 mg apraglutide
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 or 10 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Treatment with once-weekly 5- and 10-mg apraglutide doses significantly increased urine volume output by an adjusted mean of 714 ml/day (95% CI, 490-939; P < .05) and 795 ml/day (95% CI, 195-1394; P < .05), respectively, compared with placebo, with no significant differences between doses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, eight adults with SBS-IF were treated with once-weekly 5-mg apraglutide doses and placebo for 4 weeks,
Report a problemFND-3428797010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.